BECTON, Dickinson AND
BECTON, DICKINSON AND COMPANY
Key figures
Period Oct 2024 to Sep 2025ConsolidatedU.S. GAAP
RevenueDisclosed
US$21.8B
Operating marginCalculated
11.8%
Net assets to total assetsCalculated
45.9%
Company profile
Tables scroll sideways
Disclosed data
Profitability
★★★☆☆position among all companies
11.8%
Growth (revenue, 4-year average)
★★☆☆☆position among all companies
3.4%
Capital efficiency
★★☆☆☆position among all companies
6.6%
Revenue and profit
Performance, financial position and capital allocation
BECTON, Dickinson AND
Recent performance trends
BECTON, Dickinson AND
Cash flow trends
Consolidated indicators (9 items)
| Item | 4 years ago | 3 years ago | 2 years ago | Last year | This year |
|---|---|---|---|---|---|
| Net sales | US$19.1 billion | US$18.9 billion | US$19.4 billion | US$20.2 billion | US$21.8 billion |
| Operating income | US$2.2 billion | US$2.3 billion | US$2.1 billion | US$2.4 billion | US$2.6 billion |
| Net income | US$2.1 billion | US$1.8 billion | US$1.5 billion | US$1.7 billion | US$1.7 billion |
| Total assets | US$53.9 billion | US$52.9 billion | US$52.8 billion | US$57.3 billion | US$55.3 billion |
| Shareholders' equity | US$23.7 billion | US$25.3 billion | US$25.8 billion | US$25.9 billion | US$25.4 billion |
| Net cash provided by (used in) operating activities | US$4.1 billion | US$2.5 billion | US$3.0 billion | US$3.8 billion | US$3.4 billion |
| Net cash provided by (used in) investing activities | US$-1.9 billion | Could not be retrieved | US$-0.7 billion | US$-5.5 billion | US$-0.8 billion |
| Net cash provided by (used in) financing activities | US$-3.3 billion | Could not be retrieved | US$-2.0 billion | US$2.1 billion | US$-3.6 billion |
| Cash and cash equivalents | US$2.3 billion | US$1.0 billion | US$1.4 billion | US$1.7 billion | US$0.6 billion |
Revenue scale in the same industry
BECTON, Dickinson AND
Instruments and medical devices: 43 companies · revenue · largest first・each company’s latest fiscal year・Consolidated・Disclosed
- 1 Thermo Fisher ScientificFY Dec 2025 US$44.6B
- 2 Northrop Grumman Corp /DE/FY Dec 2025 US$42.0B
- 3 MedtronicFY Apr 2026 US$36.4B
- … 2 companies
- 6 3MFY Dec 2025 US$24.9B
- 7 DanaherFY Dec 2025 US$24.6B
- 8 BECTON, Dickinson ANDThis companyFY Sep 2025 US$21.8B
- 9 L3HARRIS TechnologiesFY Jan 2025 US$21.3B
- 10 GE Healthcare TechnologiesFY Dec 2025 US$20.6B
- … 33 companies
Sources and methodology
Basic indicators
| Item | Value | Consolidated / Non-consolidated | Source |
|---|---|---|---|
| Purchase of property, plant and equipment | US$0.8 billion | Consolidated | Disclosed |
| Cash and cash equivalents | US$0.6 billion | Consolidated | Disclosed |
| Net cash provided by (used in) financing activities | US$-3.6 billion | Consolidated | Disclosed |
| Net cash provided by (used in) investing activities | US$-0.8 billion | Consolidated | Disclosed |
| Net cash provided by (used in) operating activities | US$3.4 billion | Consolidated | Disclosed |
| Depreciation and amortization | US$2.5 billion | Consolidated | Disclosed |
| Dividends paid | US$1.2 billion | Consolidated | Disclosed |
| Net assets | US$25.4 billion | Consolidated | Disclosed |
| Net sales | US$21.8 billion | Consolidated | Disclosed |
| Operating income | US$2.6 billion | Consolidated | Disclosed |
| Net income | US$1.7 billion | Consolidated | Disclosed |
| Total assets | US$55.3 billion | Consolidated | Disclosed |
| Purchase of treasury stock | US$1.0 billion | Consolidated | Disclosed |
| Operating margin | 11.8% | Consolidated | Calculated |
| Net assets to total assets | 45.9% | Consolidated | Calculated |
| Net margin | 7.7% | Consolidated | Calculated |
| Return on equity | 6.6% | Consolidated | Calculated |